Zealand Pharma announces positive Phase 1a topline results with Kv1.3 channel blocker ZP9830 Single doses of ZP9830 were well tolerated, with no serious or severe adverse events or dose-limiting ...

The nomination of novel Kv1.3 inhibitor DPT0218 for the treatment of various immunological diseases including IBD and AD. • DPT0218 is a gut-restricted, highly potent and selective Kv1.3 inhibitor ...

Kv1.3 is a voltage-gated potassium channel that plays a crucial role in neuroinflammation and neurodegeneration in Parkinson’s disease and other disorders. Preclinical studies have shown that Kv1.3 ...

Researchers have investigated the role of the voltage-dependent potassium channel Kv1.3 in vivo in a murine model of ethanol-exposed alcohol-related liver disease (ALD).

About Kv1.3 immune sparing mechanism: autoreactive T cells are pivotal players in the pathomechanism of various autoimmune diseases. Selective pharmacological blockade of Kv1.3 attenuates autoimmune ...

VRG Therapeutics reaches monthly dosing for its lead program targeting Kv1.3 for the treatment of atopic dermatitis and other chronic inflammatory diseases. This development holds the promise of being ...

Single doses of ZP9830 were well tolerated, with no serious or severe adverse events or dose-limiting safety findings observed at any dose level ZP9830 exhibited a pharmacokinetic profile in line with ...

(RTTNews) - Zealand Pharma A/S (ZEAL) announced positive topline results from its Phase 1a clinical trial of ZP9830, a Kv1.3 channel blocker. The study met its primary endpoint, demonstrating safety ...